Go Pro

Chemed (NYSE:CHE) Shares Down 4.9% - What's Next?

Chemed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Chemed shares fell 4.9% to about $521.52 in mid-day trading, with volume below its daily average. The stock’s consensus analyst rating remains “Hold,” with a $530.75 average price target.
  • Chemed reported stronger-than-expected quarterly results, posting $6.06 in EPS versus the $5.60 estimate and revenue of $673.25 million. Revenue increased 8.8% year over year, and the company issued fiscal 2026 EPS guidance of $25.00–$25.75.
  • The company raised its quarterly dividend from $0.60 to $0.70 per share, equivalent to an annualized $2.80 payout and a 0.5% yield. Insiders have sold 6,537 shares worth approximately $3.4 million over the past 90 days, while institutional investors own 95.85% of the stock.
  • Five stocks we like better than Chemed.

Shares of Chemed Corporation (NYSE:CHE - Get Free Report) fell 4.9% during mid-day trading on Thursday . The company traded as low as $519.51 and last traded at $521.5150. Approximately 131,404 shares were traded during trading, a decline of 39% from the average daily volume of 214,262 shares. The stock had previously closed at $548.56.

Analyst Ratings Changes

CHE has been the subject of a number of analyst reports. Weiss Ratings raised shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. Oppenheimer boosted their price target on Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Royal Bank Of Canada increased their price objective on shares of Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a research report on Thursday, July 30th. Bank of America restated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Chemed currently has an average rating of "Hold" and a consensus price target of $530.75.

View Our Latest Report on Chemed

Chemed Price Performance

The firm has a market cap of $6.82 billion, a P/E ratio of 26.08, a PEG ratio of 2.06 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The company's 50-day moving average is $506.04 and its two-hundred day moving average is $448.64.

Chemed (NYSE:CHE - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. The company had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts anticipate that Chemed Corporation will post 23.18 EPS for the current fiscal year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be issued a dividend of $0.70 per share. This is an increase from Chemed's previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Monday, August 17th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. Chemed's payout ratio is presently 14.06%.

Insiders Place Their Bets

In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $541.04, for a total value of $541,040.00. Following the sale, the executive vice president owned 13,912 shares in the company, valued at $7,526,948.48. This trade represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Patrick P. Grace sold 190 shares of the business's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the sale, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. The trade was a 5.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 6,537 shares of company stock valued at $3,406,014. 3.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Chemed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Monetary Solutions Ltd bought a new stake in shares of Chemed during the fourth quarter worth about $25,000. Los Angeles Capital Management LLC bought a new position in Chemed during the 4th quarter worth $26,000. BOK Financial Private Wealth Inc. acquired a new stake in shares of Chemed in the fourth quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Chemed during the second quarter worth about $34,000. Finally, Versant Capital Management Inc lifted its stake in shares of Chemed by 7,500.0% in the second quarter. Versant Capital Management Inc now owns 76 shares of the company's stock worth $35,000 after acquiring an additional 75 shares during the period. Institutional investors own 95.85% of the company's stock.

Chemed Company Profile

(Get Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines